# EDGAR Filing Document

**Accession Number:** 0001472012
**File Stem:** 0001104659-23-033086
**Filing Date:** 2023-3
**Character Count:** 16633
**Document Hash:** da281f7611031be211df06e4e324574d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-033086.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001104659-23-033086

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20230316

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Immunome Inc.
- **CENTRAL INDEX KEY:** 0001472012
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 770694340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39580
- **FILM NUMBER:** 23737240

**BUSINESS ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341
- **BUSINESS PHONE:** 610-321-3700

**MAIL ADDRESS:**
- **STREET 1:** 665 STOCKTON DRIVE
- **STREET 2:** SUITE 300
- **CITY:** EXTON
- **STATE:** PA
- **ZIP:** 19341

?xml version="1.0" encoding="utf-8"?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

------

**FORM 8-K**

------

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

**Date of Report (Date of earliest event reported): March 16, 2023**

------

**Immunome, Inc.**

**(Exact name of registrant as specified in its charter)**

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39580** | **77-0694340** |
| **(state or other jurisdiction <br> of incorporation)** | **(Commission <br> File Number)** | **(I.R.S. Employer <br> Identification No.)** |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;**665 Stockton Drive, Suite 300 <br> Exton, Pennsylvania** | &nbsp;&nbsp;**19341** |
| &nbsp;&nbsp;**(Address of principal executive offices)** | &nbsp;&nbsp;**(Zip Code)** |

---

**Registrant's telephone number, including area code: (610** **) 321-3700**

**Not applicable**

**(Former name or former address, if changed since last report.)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

---

| |
|:---|
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| Title of each class | Name of each exchange<br> on which registered |
| **Common Stock, $0.0001 par value per share** **IMNM** | **The Nasdaq Capital Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.** |

---

On March 16, 2023, Immunome, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2022. A copy of the press release is furnished herewith as Exhibit 99.1.

The information furnished in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| [99.1](tm239583d1_ex99-1.htm) | [Press Release dated March 16, 2023 (furnished herewith)](tm239583d1_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **IMMUNOME, INC.** | **IMMUNOME, INC.** |
| By: | /s/ Purnanand D. Sarma |
|  | Purnanand D. Sarma, Ph.D. |
|  | President and Chief Executive Officer |

---

Dated: March 16, 2023

## Exhibit 99.1

**Exhibit 99.1**

**Immunome Reports Fourth Quarter and Full Year 2022 Financial Results**

**EXTON, Pa. – March 16, 2023** - Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell platform to discover and develop first-in-class antibody therapeutics to improve patient care, today reported financial results for the fourth quarter ended December 31**,** 2022 and provided a corporate update.

"Looking back on the past year, the transformative strategic collaboration with AbbVie highlighted the disruptive nature of our discovery platform in finding novel antibody-target pairs based on human memory B-cell response ," stated Purnanand Sarma, Ph.D., President and CEO of Immunome. "We look forward to continuing to execute on our momentum throughout the upcoming year as we advance our pipeline, including an IND submission for our lead oncology program, IMM-ONC-01 (anti-IL-38 antibody), and working closely with Abbvie on our collaboration to ultimately make a difference in cancer patients' lives."

**Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;· **AbbVie and Immunome <u>Announced Strategic Collaboration</u> to Discover Multiple Novel Oncology Targets.** In January 2023, Immunome entered into a strategic collaboration and option
 agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from
 three specified tumor types derived from Immunome's Discovery Engine. Key financial
 terms of the collaboration and option agreement include:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· $30
 million upfront

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· $70
 million in platform milestones

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Low
 single digit millions options payments per target

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· $120
 million per target in development and first commercial sale milestone

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· $150
 million per target in sales based milestones

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Tiered
 royalties on global sales

&nbsp;&nbsp;&nbsp;&nbsp;· **Preclinical Data on Novel Anti-EPN1 Antibody IMM20059 at the Society for Immunotherapy of Cancer's 37<sup>th</sup> Annual Meeting.** In November 2022, Immunome <u>presented a poster presentation of IMM20059</u>, Immunome's novel anti-EPN1 antibody, at the SITC Annual Meeting. IMM20059
 in combination with anti-PD-L1 atezolizumab demonstrated significant tumor regression compared
 to IMM20059 or atezolizumab treatment alone, suggesting a potential combinatorial effect,
 or a greater than 50% reduction in tumor volume (p<0.05), between the two anti-tumoral
 pathways.

&nbsp;&nbsp;&nbsp;&nbsp;· **Immunome <u>published a paper</u> highlighting the importance of tumor and lymph node-derived B cells for the discovery of antibodies directed at potentially novel targets.** 

&nbsp;&nbsp;&nbsp;&nbsp;· **IMM-BCP-01 Update (COVID-19 Antibody Cocktail**): Immunome has decided to seek a partner in order
 to continue the trial and for any further development activities. Immunome has successfully
 completed dosing of the first cohort of patients in a Phase 1b with no significant treatment-related
 adverse events.

**Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Cash and cash equivalents:** As of December 31, 2022 cash and cash equivalents totaled $20.3 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Research and development (R&D) expenses:** R&D expenses for the three months ended December
31, 2022, were $4.3 million. R&D expenses for the year ended December 31, 2022 were $23.3 million.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **General and administrative (G&A) expenses:** G&A expenses for the three months ended December
31, 2022, were $3.5 million. G&A expenses for the year ended December 31, 2022 were $13.6M.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· **Net loss:** Net loss attributable to common stockholders was $7.8 million, or $0.64 per share,
for the three months ended December 31, 2022. Net loss attributable to common stockholders was $36.9 million, or $3.09 per share, for
the year ended December 31, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· As
of December 31, 2022, Immunome has 12,128,843 shares of common stock outstanding.

**About Immunome** 

Immunome is a biopharmaceutical company that utilizes its proprietary human memory B cell platform to discover and develop antibody therapeutics to improve patient care. The company's focus is on discovering and developing therapeutics in oncology internally and in collaboration with our partners. For more information, please visit <u>www.immunome.com</u> or follow us on <u>Twitter</u> and <u>LinkedIn</u>.

**About Immunome's Discovery Engine**

Immunome's proprietary Discovery Engine identifies novel therapeutic antibodies and their targets through an unbiased interrogation of human memory B cells, highly educated components of the immune system, isolated from patients. Memory B cells are key elements in the human immune system response to disease as they produce specific, high-affinity antibodies that bind to cancer antigens or pathogens. Immunome's Discovery Engine incorporates high-throughput screening to enable efficient, unbiased, broad, and deep functional evaluation of patient memory B cell repertoires to identify antibodies directed at novel targets. The functional data we generate differentiates our approach from those that use deep sequencing of B cells to identify dominant clones that are common within and across patients and assumes genomic dominance is a hallmark of therapeutic utility.

For more information, please visit <u>www.immunome.com</u>.

**Forward-Looking Statements**

This press release contains "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include, without limitation, express or implied statements that are not historical fact regarding matters such as: Immunome's and its collaborators' ability to achieve anticipated discovery, development and commercial milestones; the timing and results of preclinical studies and clinical trials; regulatory submissions and actions; translation of preclinical data into clinical safety and efficacy; and therapeutic potential and benefits of, and possible need and demand for, Immunome's programs and development candidates. Forward-looking statements may be identified by the words "anticipate," "believe," "estimate," "expect," "intend," "plan," "project," "suggest," "can," "may," "will," "could," "should," "seek," "potential" and similar words, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on Immunome's current expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including, but not limited to Immunome's ability to execute on its strategy, R&D efforts and collaborations with third parties, Immunome's ability to fund operations and raise capital; Immunome's reliance on vendors; the competitive landscape and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in Immunome's Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 16, 2023, and elsewhere in Immunome's other filings and reports with the SEC. Forward-looking statements contained in this announcement are made as of this date, and Immunome undertakes no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law. In this press release, we may discuss our current and potential future product candidates that have not yet completed clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority, including expectations about their therapeutic potential and benefits thereof. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied.

**IMMUNOME, INC.**

Condensed Balance Sheets

(In thousands, except share data)

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2022** | **2021** |
| **Assets** |  |  |
| Current assets: |  |  |
| Cash and cash equivalents | $20323 | $49229 |
| Prepaid expenses and other current assets | 2326 | 7409 |
| &nbsp;&nbsp;&nbsp;Total current assets | 22649 | 56638 |
| Property and equipment, net | 681 | 855 |
| Operating right-of-use asset, net | 284 |  |
| Restricted cash | 100 | 100 |
| Deferred offering costs | 332 | 332 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $24046 | $57925 |
| **Liabilities and stockholders' equity** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $2400 | $3077 |
| Accrued expenses and other current liabilities | 4931 | 6651 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 7331 | 9728 |
| Other long-term liabilities | 62 | 12 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 7393 | 9740 |
| Commitments and contingencies (Note 8) |  |  |
| Stockholders' equity: |  |  |
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2022 and December 31, 2021 |  |  |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 12,128,843 shares issued and outstanding at December 31, 2022 and 12,110,373 shares issued and outstanding at December 31, 2021 | 1 | 1 |
| Additional paid-in capital | 132653 | 127289 |
| Accumulated deficit | (116001) | (79105) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 16653 | 48185 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities and stockholders' equity | $24046 | $57925 |

---

**IMMUNOME, INC.**

Condensed Statements of Operations

(In thousands, except share and per share data)

---

| | | |
|:---|:---|:---|
|  | **Year ended December 31,** | **Year ended December 31,** |
|  | **2022** | **2021** |
| Operating expenses: |  |  |
| &nbsp;&nbsp;Research and development | $23272 | $14110 |
| &nbsp;&nbsp;General and administrative | 13629 | 11094 |
| Total operating expenses | 36901 | 25204 |
| Loss from operations | (36901) | (25204) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;Other income |  | 503 |
| &nbsp;&nbsp;Interest income (expense), net | 5 | (10) |
| Total other income | 5 | 493 |
| Net loss | $(36896) | $(24711) |
| Deemed dividend arising from warrant modification | (622) |  |
| Net loss attributable to common stockholders | $(37518) | $(24711) |
| Per share information: |  |  |
| Net loss per common share, basic and diluted | $(3.09) | $(2.14) |
| Weighted-average common shares outstanding, basic and diluted | 12126573 | 11538668 |

---

**Immunome Contact**<br> Corleen Roche<br> Chief Financial Officer<br> Immunome, Inc.<br> <u>investors@immunome.com</u>

**Investor Contact**<br> Laurence Watts<br> Managing Director<br> Gilmartin, LLC<br> <u>laurence@gilmartinir.com</u>

**Media Contact**<br> Gwen Schanker<br> Account Supervisor<br> LifeSci Communications<br> <u>gschanker@lifescicomms.com</u>